PROF 財務： Profound Medical Corp. AI 分析

首頁

股票

PROF

財務狀況

PROF 財務

Profound Medical Corp.

$6.43

-1.53%

$-0.1

收盤價：Apr 02, 16:00:00 GMT-4

$6.43

盤後：Apr 02, 18:53:01 GMT-4

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

PROF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
營收	16	16	10	7	6	6
營收年增率 (YoY)	45%	60%	43%	17%	0%	-14%
營收成本	4	4	3	2	3	3
毛利	11	11	7	4	3	2
銷售、一般及管理費用	32	32	23	18	17	17
研發	20	20	16	14	14	--
營業費用	52	52	40	32	32	33
其他非營業收入 (費用)	--	--	--	0	0	0
稅前淨利	-42	-42	-27	-28	-28	-30
所得稅費用	0	0	0	0	0	0
淨利	-42	-42	-27	-28	-28	-30
淨利成長	56%	56%	-4%	0%	-7%	43%
稀釋後流通股數	30.57	30.23	24.76	21.18	20.82	20.46
股數年變動 (YoY)	19%	22%	17%	2%	2%	18%
每股盈餘 (稀釋)	-1.41	-1.4	-1.12	-1.35	-1.38	-1.5
每股盈餘成長率	33%	25%	-17%	-2%	-8%	20%
自由現金流	-38	-38	-23	-22	-25	-22
每股自由現金流	--	--	--	--	--	--
毛利率	68.75%	68.75%	70%	57.14%	50%	33.33%
營業利益率	-256.25%	-256.25%	-330%	-400%	-483.33%	-500%
淨利率	-262.5%	-262.5%	-270%	-400%	-466.66%	-500%
自由現金流利潤率	-237.5%	-237.5%	-229.99%	-314.28%	-416.66%	-366.66%
EBITDA	-41	-41	-33	-27	-28	-29
EBITDA 利潤率	-256.25%	-256.25%	-330%	-385.71%	-466.66%	-483.33%
EBITDA 中的折舊與攤銷	0	0	0	1	1	1
EBIT	-41	-41	-33	-28	-29	-30
EBIT 利潤率	-256.25%	-256.25%	-330%	-400%	-483.33%	-500%
有效稅率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Profound Medical Corp. 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），Profound Medical Corp. 的總資產為 $77，淨損失為 $-42

PROF 的關鍵財務比率是什麼？



Profound Medical Corp. 的流動比率為 7，淨利潤率為 -262.5，每股銷售為 $0.52。

Profound Medical Corp. 的收入按細分市場或地理位置如何劃分？



Profound Medical Corp. 最大收入來源為 Recurring - Non-capital，在最近的收益報告中收入為 11,288,483。就地區而言，United States 是 Profound Medical Corp. 的主要市場，收入為 10,069,217。

Profound Medical Corp. 是否盈利？



無，根據最新的財務報表，Profound Medical Corp. 的淨損失為 $-42

Profound Medical Corp. 有負債嗎？



是的，Profound Medical Corp. 的負債為 11

Profound Medical Corp. 的流通股有多少？



Profound Medical Corp. 的總流通股為 36.29

關鍵數據

前收市價

$6.53

開盤價

$6.33

當日範圍

$6.26 - $6.57

52週區間

$3.76 - $8.95

交易量

39.5K

平均成交量

259.1K

股息收益率

每股盈餘 (TTM)

-1.41

市值

$233.3M

什麼是 Profound Medical Corp.？

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

功能特性

資源